Phase 1 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with non-small cell lung cancer (NSCLC) with a specific gene change (ALK or ROS1 fusion), malignant pleural mesothelioma, esophageal cancer, or ovarian cancer at an advanced stage (for the initial phase of the trial).
• For the expansion phase: either you have NSCLC with an ALK/ROS1 gene change and have already tried targeted therapy (TKI) but it stopped working or you could not tolerate it, with a specific protein marker (pFAK) score of 10 or above — OR you have NSCLC with an ALK/ROS1 gene change and have never had targeted therapy before.
• You are generally well enough to carry out light activity and care for yourself (rated 0 or 1 on a standard fitness scale used by doctors).
• Your life expectancy is at least 3 months.
• You have at least one tumour that can be measured on a scan.
• Your blood counts and bone marrow are working well enough (confirm with trial site).
• Your kidneys and liver are functioning well enough (confirm with trial site).
• Your heart is functioning normally.
• If you have cancer that has spread to the brain, your symptoms are currently stable and under control.
• If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before taking the first dose.
• You and your partner are willing to use effective contraception during the trial and for at least 30 days after the last dose.
• You are able to understand the trial information and are willing to sign a consent form.
• You are willing and able to attend all required visits and follow-up appointments.
• You can provide a tumour tissue sample (either a recent or previously stored sample) taken within 28 days before treatment starts; if no sample is available, this may be discussed with the trial team.
• You are willing to provide a fresh tumour tissue sample taken before treatment begins.

Who may not be able to join:

• You are currently receiving other cancer treatments such as chemotherapy, radiotherapy, immunotherapy, or biological therapy, or have taken part in another experimental drug trial within the past 28 days.
• You have taken targeted therapy (TKI) within the 8 days before starting the trial drug.
• You still have significant side effects from a previous cancer treatment that have not resolved.
• You have difficulty swallowing, problems absorbing medicines, or another condition that could prevent you from taking the trial drug properly.
• You have a significant history of heart or cardiovascular disease.
• You have not fully recovered from a recent operation, or you have had major surgery within the past 28 days or minor surgery within the past 14 days.
• You have an active, serious infection, including HIV or active hepatitis B or C.
• You have a known allergy to any ingredient in the trial drug or similar medicines.
• You are pregnant, breastfeeding, or planning to become pregnant during the trial.
• You have any other condition that, in the opinion of the doctor, could put your safety at risk or affect the trial results.
• You have taken certain medications that affect how the body processes drugs (specifically moderate inhibitors or inducers of CYP3A4, CYP2C9, or CYP2C19) within the week before starting the trial (confirm with trial site).
• You have taken certain other medications with a very narrow safe dosing range that are broken down by a specific liver enzyme (CYP3A4 substrates with a narrow therapeutic window) within the week before starting the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.